Data-driven subclassification of type 2 diabetes in Mexico: a conceptual framework to improve diabetes care
Type 2 diabetes (T2D) is a heterogeneous disease and a major public health concern in low- and middle-income countries (LMICs). To address this heterogeneity, several subgroup classification frameworks have been proposed. Among them, the most widely used is the data-driven classification proposed by Ahlqvist et al., which includes severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD), and mild age-related diabetes (MARD). However, reproducing this framework is limited by the need for specialized measurements of beta-cell function and insulin resistance, which are not routinely available in most clinical or epidemiological settings in LMICs. To overcome these barriers, we derived a classification algorithm to reproduce these diabetes subgroups. Here, we present a four-step roadmap in which this framework may help characterize T2D heterogeneity across Mexico, potentially guide pathophysiology-oriented treatment strategies, support public health monitoring, and enhance our understanding of T2D heterogeneity to improve diabetes care in our country.
Authors
- Neftalí Eduardo Antonio-Villa (ORCID: https://orcid.org/0000-0002-6879-1078)
- Omar Yaxmehen Bello‐Chavolla (ORCID: https://orcid.org/0000-0003-3093-937X)
- Mario Cesar Torres-Chavez (ORCID: https://orcid.org/0000-0003-1843-3077)
- Jaretzy García-Manteca
- Jacqueline A. Seiglie
Institutions
- Harvard University (US)
- Universidad Autónoma de Baja California (MX)
- Massachusetts General Hospital (US)
- Instituto Nacional de Pediatria (MX)
- Universidad La Salle (MX)
- Harvard Global Health Institute (US)
- Instituto Nacional de Cardiología (MX)
Publication Details
- Journal
- The Lancet Regional Health - Americas
- Published
- 2026-07-17
- DOI
- https://doi.org/10.1016/j.lana.2026.101576
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00